Navigation
banner
Together we Drive the Future

Drug Design & Medicinal Chemistry

2017-07-232017-09-162017-08-16
EARLY BIRD DISCOUNT! Register by Aug 16, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


registration button

European Pharma Summit


Drug Design & Medicinal Chemistry

GPCR Targeted Screening

Kinase Inhibitors in Drug Discovery
 
 

Subscribe for updates



Dear Colleague,

We are excited to announce the 12th Drug Design & Medicinal Chemistry Conference, to be held November 16-17, 2016 in Berlin, Germany. This meeting will provide a multi-disciplinary forum for industry and academia colleagues to gather and explore the changing landscape of drug discovery in emerging target classes and chemical biology approaches for discovering new medicines. Leaders in the field will present on hot topics such as protein-protein interactions, overcoming resistance in drug design, allosteric inhibitors, and many more. Attendees will also have the opportunity to meet colleagues during dedicated networking sessions and form new connections.

Session topics:

  1. Opening Plenary: Chemical Biology for Target Identification and Validation
  2. Tools and Technologies for Drug Discovery
  3. Novel Computational Methods & Predictive Models
  4. Targeting the Regulatory Proteome
  5. Epigenetic Based Inhibitors
  6. Closing Plenary: Hot Topics in Drug Discovery for the Future

We hope to see you there!


Best regards,

The 2017 Advisory Committee

2017 Advisory Board Members
Sharad Verma, Johns Hopkins University School of Medicine
Camila Esguerra, University of Oslo
Simone Fulle, BioMed X Innovation Center
Frank Boeckler, Eberhard Karls Universität Tübingen
Philippe Roche, National Center for Scientific Research
Guido Zaman, Netherlands Translational Research Center
Lori Gavrin, GlaxoSmithKline
Phil Kym, AbbVie
Ingo Mugge, Alkermes
Constance Höfer, Vitilis
Tauseef Butt, Progenra Inc.
Daniel Zwilling, Circuit Therapeutics
Dehua Pei, Ohio State University
Georgia McGaughey, Vertex Pharmaceuticals
Gisbert Schneider, ETH Zürich